Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Trial Profile

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Vitamin K antagonists
  • Indications Stroke; Transient ischaemic attacks
  • Focus Adverse reactions
  • Acronyms PRODAST

Most Recent Events

  • 09 May 2022 Status changed from active, no longer recruiting to completed.
  • 29 Sep 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.
  • 02 Dec 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top